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Abstract
Protein hydroxylation is a post-translational modification catalyzed by 2-oxoglutarate-dependent 
dioxygenases. The hydroxylation modification can take place on various amino acids, including 
but not limited to proline, lysine, asparagine, aspartate and histidine. A classical example of this 
modification is hypoxia inducible factor alpha (HIF-α) prolyl hydroxylation, which affects HIF-α 
protein stability via the Von-Hippel Lindau (VHL) tumor suppressor pathway, a Cullin 2-based E3 
ligase adaptor protein frequently mutated in kidney cancer. In addition to protein stability 
regulation, protein hydroxylation may influence other post-translational modifications or the 
kinase activity of the modified protein (such as Akt and DYRK1A/B). In other cases, protein 
hydroxylation may alter protein-protein interaction and its downstream signaling events in vivo 
(such as OTUB1, MAPK6 and eEF2K). In this review, we highlight the recently identified protein 
hydroxylation targets and their pathophysiological roles, especially in cancer settings. Better 
understanding of protein hydroxylation will help identify novel therapeutic targets and their 
regulation mechanisms to foster development of more effective treatment strategies for various 
human cancers.
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1. Introduction
1.1 2-oxoglutarate-dependent dioxygenases
2-oxoglutarate (2-OG)-dependent dioxygenases are iron-containing enzymes that pair 
substrate oxidation to the conversion of 2-OG to succinate and carbon dioxide [1]. The 2-
OG-dependent oxygenase catalyzes the hydroxylation of proline and lysine residues, which 
was first identified in collagen biosynthesis [2]. Subsequently, it has been demonstrated that 
this type of post-translational modification also affects intracellular proteins. Specifically, 
the hypoxia-inducible factors (HIFs) have been found to be hydroxylated on both proline 
and asparagine residues by the prolyl hydroxylase domain proteins PHD1, PHD2, PHD3 
(also called Egl nine homolog EglN2, EglN1, and EglN3) and factor inhibiting HIF (FIH), 
respectively [3]. Up to date, about seventy 2-OG dependent dioxygenases have been 
identified in the human genome [4]. According to their biological functions, it is possible to 
distinguish them into three major subclasses: histone demethylases, DNA/RNA 
demethylases/hydroxylases and protein hydroxylases [5].
Histone methylation is performed by the family of lysine and arginine methyltransferases, 
which can transfer up to three methyl groups to histone lysines and asparagines, 
subsequently triggering different activities according to the recruitment of specific effector 
proteins by the readers [6]. Importantly, the JumonjiC (JMJC) domain-containing histone 
demethylases, which can be further divided into seven subfamilies (KDM2-8), remove 
methyl groups from all three methyl lysine states, with concomitant production of succinate, 
carbon dioxide, and subsequent release of formaldehyde [7, 8].
Eukaryotic DNA and RNA methylation is primarily catalyzed by DNA and RNA 
methyltransferases, respectively, which epigenetically modulate cell fate without altering the 
nucleic acid sequence. DNA/RNA can be also methylated by endogenous and/or exogenous 
alkylating agents in a process referred to as methylation damage [9]. In humans, both 
regulatory and aberrant methylation can be oxidatively reversed by a non-heme iron-
dependent dioxygenase superfamily composed of nine members (alkylation repair homologs 
ALKBH1-8, and fat-mass and obesity-associated FTO) [9]. Recently, the ten-eleven 
translocation (TET)/J-binding protein (JBP) family proteins (TET1, TET2, and TET3; JBP1 
and JBP2), also belonging to the family of iron- and 2-OG-dependent dioxygenases, have 
been found to oxidize 5-methylcytosine [10].
In this review, we will mainly focus on protein hydroxylases. The primary residue to be 
hydroxylated in proteins is proline, and accordingly the hydroxylases that catalyze this 
reaction are called prolyl hydroxylases. In addition to proline, asparagine, aspartate, lysine 
and histidine have also been found to be hydroxylated in cells [11–14].
1.2 Prolyl Hydroxylases
The HIFs are transcription factors that coordinate cellular responses to low oxygen levels, 
aiming at increased oxygen delivery and reduced oxygen consumption [3]. Transcriptionally 
active HIFs are heterodimers composed of an alpha and ARNT (aryl hydrocarbon receptor 
nuclear translocator) subunits. In humans, the alpha subunit has three isoforms, namely 
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HIF-1α, HIF-2α and HIF-3α. Different from the ARNT subunit that is constitutively 
expressed, the protein stabilization of the alpha subunit is oxygen-sensitive [3].
In normoxic conditions, HIFs have been found to be hydroxylated on one or two proline 
residues by the prolyl hydroxylase domain proteins PHD1/EglN2, PHD2/EglN1, and PHD3/
EglN3 [15]. Specifically in regards to HIF-1α, its hydroxylation on proline 402 (Pro402) 
and 564 (Pro564) by PHDs triggers its recognition by a multimeric E3 ubiquitin ligase 
complex formed by the von Hippel-Lindau tumor suppressor protein (pVHL), elongin B and 
C, Cullin 2 (CUL2) and RING-box 1 (RBX1) proteins. Homologous to the Skp, Cullin, F-
box containing (SCF) family of E3 ubiquitin ligase complexes, this complex targets HIF-1α 
for ubiquitin-mediated proteasomal degradation (Fig. 1A) [16]. It is important to point out 
that even though all three enzymes contribute to HIF regulation, PHD2/EglN1 is the major 
prolyl hydroxylase mediating HIF-1α hydroxylation in vivo [17–20].
Under hypoxic conditions, HIFs are not hydroxylated and, thus, can bind to the hypoxia-
response elements (HRE) in the promoter of more than one hundred target genes involved in 
cell survival in low oxygen conditions [21]. These targeted genes include metabolic genes 
such as the glucose transporter 1 (GLUT1), the vascular endothelial growth factor (VEGF) 
that promotes angiogenesis, and erythropoietin (EPO) that controls erythropoiesis. 
Transforming growth factor alpha (TGFα), implicated in cell proliferation and survival, and 
C-X-C chemokine receptor type 4 (CXCR4), important for cell migration and invasion, are 
also characterized HIF targets (Fig. 1B) [22]. As all of these pathways promote the growth 
and progression of many tumors, HIFs are generally considered as attractive therapeutic 
targets in cancer.
Since the identification of HIF hydroxylation, much effort has been devoted to better 
understand whether and how prolyl hydroxylation regulates signaling pathways beyond the 
HIF-pathway. Over the course of the last decades, a handful of substrates have been 
identified as bona fide PHD substrates. Among them, the centrosomal protein of 192 kDa 
CEP192 and the inhibitor of nuclear factor kappa-B kinase subunit beta IKBKB are PHD1 
substrates [23, 24], while the isoform 2 of pyruvate kinase PKM2 and the β-adrenergic 
receptor II are PHD3 substrates. Since these targets have been reviewed recently [5, 25], this 
review will largely focus on other most recently identified substrates.
1.3 Regulation of Prolyl Hydroxylases
PHD/EglN protein expression is tissue- and context-dependent. PHD2/EglN1 is ubiquitously 
expressed, whereas PHD1/EglN2 and PHD3/EglN3 are mainly observed in testis and heart, 
respectively [26]. PHDs are transcriptionally regulated by their downstream target HIF 
pathway [27, 28]. Of note, HIF-induced PHD3/EglN3 expression provides a negative 
feedback regulating HIFs in hypoxic conditions [29]. Furthermore, PHD2/EglN1 and PHD1/
EglN2 can be transcriptionally. regulated by estrogen pathways in breast cancer cells [30–
34]. At the protein level, the abundance of PHD3/EglN3, and to a lesser extent of PHD1/
EglN2, is regulated by the E3 ubiquitin ligases SIAH1/2 in a proteasomal-dependent manner 
[35]. However, the manipulation of PHD/EglN catalytic activities has been a mystery for a 
long time. Previous research has reviewed extensively on how PHDs/EglNs serve as 
important nutrient sensors since their activity is regulated by the availability of oxygen, 
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Fe2+, ascorbic acid and 2-OG [5]. Here we summarize the latest development on how PHD 
activity can be regulated.
Recent work from different groups reported that 2-hydroxyglutarate (2-HG), a small 
molecule produced by mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) in glioblastoma, 
could manipulate dioxygenase catalytic activities, including PHDs/EglNs [36–40]. 
Mechanistically, 2-HG competes with 2-OG to bind with PHDs, leading to the accumulation 
of HIF-α [36]. However, some other findings demonstrated that the (R)-enantiomer of 2-
HG, opposing to (S)-2HG, can largely stimulate PHD/EglN activities, diminish HIF-α 
levels, and contribute to the proliferation of human glioma and leukemia cells, therefore 
demonstrating that HIF-α functions as a tumor suppressor in the tissue-context of brain 
tumors or leukemia [38, 39].
More recently, L-cysteine has been reported to induce recombinant PHD2/EglN1 catalytic 
activity in an ascorbate-free condition in vitro and in cells [41]. Free cysteine was shown to 
protect PHDs/EglNs from self-catalyzed inactivation due to its oxidation [42–45]. 
Accordingly, the PHD/EglN proteins, previously recognized as oxygen sensors [3], now 
have also been defined as cysteine sensors. Physiologically, L-cysteine-mediated PHD/EglN 
protection can be antagonized by the presence of L-glutamate through inhibiting the 
glutamate-cysteine antiporter xCT [46, 47]. In certain cancers, such as triple-negative breast 
cancer (TNBC), the paracrine secretion of glutamate decreases the amount of free cysteine, 
leading to PHD/EglN inactivation and subsequent HIF accumulation [41], which has been 
shown to promote the growth, invasion and metastasis in both normoxic and hypoxic 
conditions [48, 49].
1.4 Other protein hydroxylases
In addition to prolyl hydroxylation, there have been reports showing that some proteins can 
be hydroxylated on asparagine, aspartate, lysine and histidine residues. For example, factor 
inhibiting HIF (FIH) can hydroxylate HIF on the asparagine 803 (Asn803) residue, which 
affects its binding with the transcriptional co-activator p300/cyclic AMP response element-
binding protein (CBP), thereby inhibiting HIF transcriptional activity (Fig. 1C) [12]. It has 
been found that FIH can also hydroxylate aspartate residues in cytoskeletal ankyrinR and 
ankyrinB, leading to a decrease in their interaction with the cytoplasmic domain of band3 
(CDB3) [13]. JMJD6, an enzyme reported to contain both arginine demethylase and lysine 
hydroxylase activity, has been shown to hydroxylate the splicing factor U2 small nuclear 
ribonucleoprotein auxiliary factor 65-kDa subunit (U2AF65) on lysine residues, leading to 
the alteration of some endogenous and reporter gene alternative RNA splicing [11]. 
Moreover, JMJD6 was shown to promote lysine hydroxylation on histones [50]. The 
dioxygenase NO66 can act as both a histone demethylase and a ribosomal histidine 
hydroxylase, catalyzing the hydroxylation of 60S ribosomal protein L8 on histidine 216 
(His216), which raises the fascinating idea of a potential translational regulation by 
hydroxylases [14].
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1.5 Mouse models of key proline or asparagine hydroxylases
A functional hypoxic response is essential for survival, as highlighted by the embryonic 
lethality of HIF-1α [51] and HIF-2α knockout mice [52]. Genetic inactivation of VHL in the 
mouse germ line also leads to embryonic death during mid-gestation, due to abnormal 
placental vascularization [53].
The prominent role of PHD2/EglN1 in oxygen sensing under basal physiological conditions 
is evidenced by the fact that PHD2/EglN1 ablation, like genetic inactivation of VHL or 
HIFs, results in severe placental and cardiac defects and, eventually, embryonic death 
between embryonic days 12.5 and 14.5, whereas PHD1/EglN2−/− and PHD3/EglN3−/− mice 
are viable and apparently normal [19, 54]. PHD1/EglN2−/− mouse shows the hypoxia 
tolerance due to its glucose metabolic switch from oxidative towards anaerobic ATP 
production [55]. Moreover, while the conditional deletion of PHD2/EglN1 in adult mice 
causes hyperactive angiogenesis and blood vessel dilation, the conditional knockout of 
PHD1/EglN2 or PHD3/EglN3 does not lead to angiogenic anomalies [19, 54] (Table 1). 
Adult mice lacking PHD2/EglN1 also display a severe erythrocytosis, due to the activation 
of the erythropoietin (EPO) pathway in the kidney. By contrast, PHD1/EglN2 or PHD3/
EglN3 deficiency does not cause any apparent dysfunction. A moderate erythrocytosis 
occurs in PHD1/EglN2 and PHD3/EglN3 double knockout mouse, and this is associated 
with the activation of the hepatic HIF-2α/EPO pathway [56].
Different studies have investigated the role of PHD2/EglN1 in various tissues using tissue-
specific knockout mice. Specifically, PHD2/EglN1 deletion in the epidermal or dermal 
tissues has been shown to improve wound healing and minimize ischemic injury by 
increasing HIF-1α cellular levels, therefore leading to the transcription of downstream 
angiogenic factors such as VEGF [57, 58]. Myeloid-specific PHD2/EglN1 knockout in mice 
promotes plaque progression by enhancing adhesion molecule expression on granulocytes 
and monocytes [59]. This is also achieved through HIF-1α pathway, as evidenced by the loss 
of the pro-atherogenic phenotype by PHD2/HIF-1α double knockout mice [60].
Distinctively, FIH deficient mice do not show apparent defects in the classical pathways 
controlled by HIF, such as angiogenesis, erythropoiesis, or development. Instead, FIH 
knockout mice demonstrate the features that highlight this dioxygenase as an important 
metabolic regulator [61]. Aside from the reduced body weight, these mice present an 
elevated metabolic rate, hyperventilation, improved glucose and lipid homeostasis. They are 
also resistant to high-fat-diet-induced weight gain and hepatic steatosis [61]. Interestingly, 
mice lacking FIH specifically in neurons display some of the main metabolic phenotypes of 
the global knockout animals, suggesting that FIH may regulate metabolism mainly through 
its function on the nervous system [61].
1.6 Therapeutic implications of PHD/EglN inhibitions in diseases
As discussed earlier, PHD2 conditional deletion leads to HIF stabilization, and consequently, 
increased levels of VEGF and EPO and enhanced angiogenesis [19, 58, 62]. These 
observations suggested that PHD inhibitors could be beneficial for patients affected by 
anemia and ischemia-related diseases. HIF stabilization may also be useful for the treatment 
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of inflammatory diseases. PHD1 and FIH have been shown to enhance inflammation [63, 
64], and PHD inhibitors such as dimethyloxalylglycine (DMOG) and FG-4497 significantly 
improve murine models of colitis [65, 66], suggesting that a hydroxylase inhibitor can be 
beneficial for blunting excessive inflammation. Over the last few years in-depth work has 
therefore been made to find PHD inhibitors by several means, such as in silico drug 
screening [67], combinatorial libraries [68] and high-throughput screening [69]. These 
efforts have led to the discovery of several compounds, four of which are currently being 
tested in human clinical trials [70].
Nevertheless, PHD inhibition can potentially cause deleterious effects that must be taken 
into account. HIF-α expression is frequently increased in numerous human diseases like 
tumors, erythrocytosis and pulmonary arterial hypertension, and some of its downstream 
targets can be inhibited for the treatment of these conditions [22]. However, it is important to 
point out that the role of HIFs in cancer is more complex than initially thought, as PHD 
inhibition has been found to impair tumor growth and invasiveness [71]. In another study, 
PHD2 inhibition in tumor cells has been shown to stimulate vessel formation yet resulting in 
tumor growth impairment. However, this effect was largely independent of HIF pathway, 
and was ascribed to the antiproliferative activity of the PHD2-driven TGFβ signaling 
pathway [72]. In order to minimize unwanted side effects, tissue-specific PHD inhibition 
should then be considered when treating specific pathological conditions. For instance, HIF 
can be selectively activated in alveolar epithelial cells when PHD inhibitors are inhaled [73]. 
Moreover, efforts should be made to seek isoform-selective PHD inhibitors, given the 
different expression and biological functions of individual PHDs [32].
1.7 Methods for the identification of novel potential protein hydroxylase substrates
Protein association detecting methods such as yeast two-hybrid screens and affinity 
purification (AP)-MS technology allowed to pinpoint certain IκB and Notch family 
members and ankyrin repeat and SOCS box protein 4 (ASB4) as additional FIH substrates 
[74–76], as well as the activating transcription factor 4 (ATF4) as a potential PHD3/EglN3 
substrate [77].
An in silico screening for the consensus sequence LXXLAP (with X referring to any amino 
acid) allowed the finding of other PHD/EglN substrates involved in glucose metabolism and 
cell cycle regulation [23, 78]. Another approach based on a pharmacological substrate-
trapping strategy linked to mass spectrometry has enabled the challenging detection of 
transient enzyme-substrate interactions, thus leading to the detection of several other FIH 
substrates [79]. It has thus become clear that hydroxylases have a large panel of downstream 
substrates, therefore regulating several cellular signaling pathways beyond the oxygen 
sensing pathway, largely through modulating HIF stability. However, since only a few 
experimental approaches proved efficient in detecting new substrates, little progress has 
been made so far in this field. As such, searching for new hydroxylation substrates becomes 
increasingly necessary in order to improve our understanding of how hydroxylation can 
modulate cellular responses to stimuli other than the hypoxic condition.
It is also important to point out that it is relatively difficult to differentiate between oxidation 
and hydroxylation from only mass spectrometry since both modifications can occur on a 
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variety of amino acid side chains. Therefore, mass spectrometry fragmentation data need to 
be at high resolution and high coverage to confirm the assignment for the modification as 
previously shown [80]. Many hydroxylation events detected by mass spectrometry may not 
be mediated by prolyl hydroxylases. Therefore, it is critical to perform in vitro 
hydroxylation assays to validate whether these sites detected from mass spectrometry can be 
hydroxylated by various prolyl hydroxylases. Moreover, it is equally important to further 
investigate whether these sites are functionally important in a physiologically relevant 
system.
Here we give an overview of recently identified hydroxylation substrates (Table 2), primarily 
focusing on the biological readouts and the potential pathological role of this intriguing post-
translational modification.
2. Novel Hydroxylation Targets and Their Cellular Functions
2.1 FOXO3a prolyl hydroxylation
Forkhead box-O (FOXO) tumor suppressors function to suppress cell proliferation and cell 
survival by transcriptionally activating specific gene targets that are wired into diverse 
cancer regulatory pathways. Activation of the phosphatidylinositide 3-kinase (PI3K) by 
extracellular growth signals leads to FOXO phosphorylation at three conserved serine/
threonine (Ser/Thr) sites by the serine/threonine kinase Akt, whereupon the FOXOs are 
translocated to the cytoplasm and degraded [81]. FOXO3a protein stability can also be 
regulated by the regulatory protein IkappaB or extracellular signal-regulated kinase (ERK)-
mediated phosphorylation [82, 83].
Notably, the role of the FOXOs in cancer has recently received increasing support from 
genetic studies in mouse and human cancer. FOXOs are deleted or mutated in a variety of 
human cancers, such as leukemia and prostate cancer [84, 85]. Overexpression of FOXO3a 
inhibits breast tumor cell growth in vitro and tumor size in vivo, suggesting that FOXO3a 
acts largely as a tumor suppressor in breast cancer [82, 83]. Consistent with these 
observations from human cancer, the mouse genetic studies from Depinho group have 
established that broad somatic deletion of all three FOXOs (FOXO1, 3 and 4) engenders a 
cancer-prone condition, thus providing formal proof that FOXOs function as tumor 
suppressors in vivo [86].
Zheng et al. used an in vitro hydroxylation screening with recombinant PHD1/EglN2 and 
identified that FOXO3a is a bona fide PHD1/EglN2 substrate. Mechanistically, FOXO3a can 
be hydroxylated by PHD1/EglN2 on two different proline residues (Pro426 and 437), which 
triggers its dissociation from the ubiquitin specific peptidase 9, X-linked (USP9x) 
deubiquitinase (Fig. 2) [87]. As a result, FOXO3a undergoes proteasomal degradation. Since 
FOXO3a was reported to be a transcriptional repressor for cyclin D1, its destabilization 
leads to cyclin D1 accumulation. This study provides mechanistic insight into how PHD1/
EglN2 transcriptionally regulates cyclin D1 in an enzymatic-dependent fashion, thereby 
contributing to breast tumorigenesis. In addition, it sheds light on the important role of 
FOXO3a and USP9x in breast cancer. Intriguingly, pVHL does not regulate FOXO3a protein 
Zurlo et al. Page 7
Biochim Biophys Acta. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
stability in this setting (Zhang Q., unpublished finding). Thus, it remains to be determined 
which E3 ligase may mediate the hydroxylated FOXO3a for degradation.
2.2 DYRK1A and DYRK1B prolyl hydroxylation
The inhibitor of differentiation (ID) protein family members (including ID1, 2, 3 and 4) are 
master regulators of stem cell function [88, 89]. During tumorigenesis, cancer cells hijacked 
their functions, therefore contributing to cancer stem cell function and tumorigenesis. 
However, the regulatory pathway of ID proteins remains largely undefined. By using 
glioblastoma cell as a model system, a recent paper by Lee et al. showed that dual-specificity 
tyrosine-(Y)-phosphorylation regulated kinases 1A and B (DYRK1A and DYRK1B) 
phosphorylate ID2 on threonine 27 (Thr27). Interestingly, PHD1/EglN2 hydroxylates 
DYRK1A and DYRK1B, thus promoting their phosphorylation and kinase activity in cells. 
As a result, ID2 is phosphorylated and prevented from interacting with pVHL, therefore 
preserving pVHL-dependent HIF-2α ubiquitination and degradation (Fig. 3A) [90].
On the other hand, in the presence of hypoxia or potentially PHD1 depletion, DYRK1A and 
DYRK1B cannot be efficiently hydroxylated or phosphorylated. Therefore, ID2 is not 
phosphorylated on Thr27, which subsequently promotes its binding with pVHL that 
displaces the scaffold protein CUL2 from its interaction with pVHL E3 ligase complex. 
Accordingly, pVHL cannot efficiently ubiquitinate HIF-2α, leading to HIF-2α accumulation 
followed by transcriptional regulation of its downstream target gene expression (Fig. 3B). 
This will contribute to glioma stemness, increased tumor growth and less favorable outcome 
in patients with glioblastoma. This elegant study reveals a novel regulatory pathway for ID2 
function in glioblastoma affected by DYRK1A and DYRK1B prolyl hydroxylation, and 
indicates the potential role of PHD1/EglN2 as a tumor suppressor in glioblastoma by 
indirectly regulating HIF-2α levels and glioma stemness. However, it remains unclear 
whether PHD1/EglN2 directly hydroxylates DYRK1A/B on proline residues. In addition, it 
will be very interesting to further determine the molecular mechanism by which DYRK1A/B 
hydroxylation affects its phosphorylation and kinase activity, which will reveal the causal 
relationship between hydroxylation and phosphorylation events.
2.3 NDRG3 prolyl hydroxylation
N-Myc downstream-regulated gene (NDRG) contains 4 family members that are well 
conserved through evolution [91]. NDRG1 was first reported to be repressed by the N- and 
c-Myc proto-oncogenes [92, 93]. However, the regulation of other NDRG family members 
remains largely unknown. A recent paper by Lee et al. demonstrates that NDRG3 can be 
hydroxylated on the Pro294, potentially by PHD2/EglN1. Subsequently, NDRG3 
hydroxylation triggers its binding with pVHL followed by NDRG3 ubiquitination and 
degradation (Fig. 4A) [94]. During tumor development, hypoxia provokes the accumulation 
of lactate that directly binds NDRG3, thus preventing its interaction with the pVHL 
complex. Therefore, NDRG3 can accumulate and contribute to downstream RAF-ERK1/2 
kinase signaling (Fig. 4B).
There is a strong dependence of lactate-induced hypoxia for cell growth, angiogenesis and 
anti-apoptosis on NDRG3-mediated ERK1/2 activity [94]. There are also several interesting 
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questions emerging from this elegant study. Firstly, does PHD2/EglN1 directly hydroxylate 
NDRG3 on Pro294 in vitro and in vivo? Secondly, it remains unclear how the interaction 
between NDRG3 and pVHL is decreased by hypoxia, and whether this could be due to the 
increased interaction between NDRG3 and lactate or to the decreased hydroxylation of 
NDRG3 under this metabolic condition. Thirdly, since hypoxia can induce PDK1 expression 
through HIF-1α, which will shift the pyruvate enzymatic reaction from producing acetyl-
CoA to producing lactate important for the glycolytic pathway [95], it is likely that HIF-1α 
also contributes to lactate production level. If this is true, it is possible that the depletion of 
HIF pathway components will decrease lactate production and diminish NDRG3 
accumulation under hypoxia. Therefore, it is likely that NDRG3 may be dependent on HIF 
signaling as a secondary effector that affects hypoxia responsive signaling in cancer.
2.4 Akt prolyl hydroxylation
VHL is a critical tumor suppressor gene that is inactivated by either mutation or 
hypermethylation in the majority of clear cell renal cell carcinoma (ccRCC), a lethal disease 
accounting for 85% of renal cancers and classically resistant to cytotoxic chemotherapy 
[96]. Preclinical studies demonstrated that Akt is frequently activated in ccRCC patients 
with pVHL loss [97], indicating the possible connection between pVHL loss and Akt hyper-
activation.
The seminal findings from Guo et al. demonstrate that Akt can be hydroxylated on Pro125 
and Pro313 residues by PHD2/EglN1 in vivo and in vitro [98]. pVHL binds directly with 
hydroxylated Akt and inhibits Akt activity, demonstrated by the decrease of Akt 
phosphorylation on threonine 308 (Thr308) and serine 473 (Ser473) [98]. Therefore, in cells 
under hypoxia or lacking functional pVHL, Akt activity is aberrantly elevated, therefore 
contributing to increased cell proliferation and tumorigenesis (Fig. 5A and 5B) [98]. 
Concerning the disease relevance, cancer-associated AKT mutations have been found to 
decrease Akt hydroxylation, therefore contributing to higher Akt phosphorylation.
By generating several Akt hydroxylation specific antibodies, this work shows the intimate 
connection between hydroxylation and kinase signaling pathways. Notably, in normoxic 
conditions, growth factor-induced Akt phosphorylationcould subsequently trigger the 
interaction of Akt with PHD2/EglN1, which in turn hydroxylates the activated Akt to 
promote pVHL-mediated suppression, presumably functioning as a negative feedback 
regulation to tightly regulate the kinase activity of Akt in vivo. Mechanistically, it also shows 
that Akt hydroxylation triggers a stronger interaction between Akt and the protein 
phosphatase 2A (PP2A) mediated by pVHL. (Fig. 5A). Interestingly enough, the Akt prolyl 
hydroxylation motif shares some similarities with the FOXO3a prolyl hydroxylation motif 
[87], raising the question of whether the “FOXO3alike” motif can be used to predict 
potential prolyl hydroxylation substrate pool in future research. This paper also suggests that 
not all of bona fide PHD/EglN substrates will carry the canonical LXXLAP HIF prolyl 
hydroxylation motif, which was identified in many proteins other than HIF such as IKKB, 
PKM2 and Cep192.
The recently identified GSPT or GPSS motif in FOXO3A and GSPS or GTPE motif in Akt, 
both of which can be proline-hydroxylated, might therefore be used to predict other putative 
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hydroxylation sites. However, the limited number of published novel hydroxylation targets 
that can be used to predict these patterns limits the power of this in silico prediction. and 
awaits future research to solidify this motif.
In contrast to the finding that Akt hydroxylation compromises its phosphorylation, 
DYRK1A and DYRK1B hydroxylation positively regulates their phosphorylation. 
Therefore, it appears that there may be distinctive mechanisms that link hydroxylation and 
phosphorylation events, which also requires further detailed study in the near future.
2.5 EPOR prolyl hydroxylation
Erythropoietin (EPO) controls erythropoiesis by binding to its receptor (EPOR) on erythroid 
progenitor cells and subsequently activating JAK-STAT signaling pathways [99]. EPO has 
been well established to be a HIF-2α target gene [100, 101]. Mutation of PHD2/EglN1 was 
reported to induce EPO production largely in a HIF-2α-dependent manner [102]. However, 
the regulation of EPOR remains largely unknown.
Heir et al. [103] showed for the first time that EPOR protein levels are regulated by PHD3/
EglN3 -mediated prolyl hydroxylation on Pro419 and Pro426 residues (Fig. 6A). Therefore, 
both hypoxia and prolyl hydroxylase inhibitors can induce EPOR protein stability. 
Mechanistically, EPOR protein stability regulation is through its binding with pVHL 
complex in a hydroxylation dependent manner and EPOR protein binds with the canonical 
pVHL substrate binding domain. Interestingly, while some of pVHL disease mutants still 
retain the ability to bind with hydroxylated HIF peptide, most of these mutants failed to bind 
with the EPOR hydroxylated peptide. This finding suggests that the EPO signaling is 
regulated by PHD3/EglN3 and the pVHL signaling pathway in human disease.
2.6 OTUB1 asparagine hydroxylation
The ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 (OTUB1) 
deubiquitinase was previously identified as a potential substrate for FIH hydroxylase [63]. 
OTUB1 was shown to be hydroxylated by FIH on the Asparagine 22 (Asn22) residue [104]. 
OTUB1 hydroxylation on Asn22 alters its binding behavior, especially with respect to 
proteins important in metabolic pathways. As a result, its hydroxylation changes the 
important pathways involved in cell metabolism. Scholz et al. [104] demonstrates a direct 
link between FIH-induced OTUB1 hydroxylation and cellular metabolism reprogramming, 
which may be important in human disease settings, especially in cancer where hypoxia 
serves as a hallmark and regulates cellular protein hydroxylation. Interestingly, OTUB1 
Asn22 hydroxylation does not necessarily change its protein stability, which further 
indicates that not all hydroxylation modifications lead to changes in protein stability. As an 
alternative explanation, hydroxylation may change the binding complex repertoires, which 
may lead to profound changes important in various human diseases, such as cancer.
2.7 MAPK6 and RIPK4 prolyl and asparagine hydroxylation
Developing an enzyme trapping strategy by treating cells with the pan-prolyl hydroxylase 
inhibitor DMOG, combined with quantitative interaction proteomics, Rodriguez et al. [80] 
were able to identify some novel FIH and PHD substrates. As a proof of principle, they 
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identified some of characterized PHD substrates from this proteomic approach, including 
CEP192 and FOXO3a [23, 80, 87]. Among potential PHD3/EglN3 binding partners/
substrates, mitogen-activated protein kinase 6 (MAPK6) has been shown to be hydroxylated 
by PHD3/EglN3 on proline 25 (Pro25), which potentially leads to its dissociation from 
HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase (HUWE1), thus 
protecting it from proteasomal degradation (Fig. 6B). Therefore, inhibition of MAPK6 
hydroxylation by various prolyl hydroxylase inhibitors decreases MAPK6 protein stability in 
cells.
This regulation is distinctive of the canonical view that prolyl hydroxylation makes protein 
more susceptible for proteasomal degradation. This suggests that prolyl hydroxylation may 
affect protein stability via distinctive mechanisms depending on specific cellular contexts 
and prolyl hydroxylases. While PHD1/EglN2 and PHD2/EglN1 hydroxylation targets may 
be subjected to proteasomal degradation pathway, PHD3/EglN3 substrates may be protected 
from degradation upon being hydroxylated, while the underlying molecular mechanism 
warrants further in-depth investigation.
In addition, FIH was found to hydroxylate receptor-interacting serine-threonine kinase 4 
(RIPK4) on asparagine residues, which did not mark RIPK4 for protein degradation. 
Interestingly, using TCF/LEF luciferase reporter to measure β-Catenin activity, RIPK4 
hydroxylation was shown to increase Wnt signaling pathway activity (Fig. 6C). By defining 
the specific phosphorylation sites that are important for RIPK4 activity, Rodriguez and 
colleagues also pointed out that RIPK4 hydroxylation might affect RIPK4 kinase activity 
determined by the appearance of phosphorylation sites in mass spectrometry. This also 
suggests an enzymatic link between RIPK4 hydroxylation and phosphorylation. However, 
future research needs to be performed to examine the causal relationship and the molecular 
mechanism underlying how RIPK4 hydroxylation may affect its phosphorylation and 
activity in the cells. Although in this study a was used to identify potential prolyl or 
asparaginyl substrates, it still remains to be determined how these potential hydroxylation 
targets may affect cellular functions in a disease setting, such as cancer.
2.8 eEF2K prolyl hydroxylation
Translation elongation is mainly controlled by eukaryotic elongation factor 2 (eEF2) 
phosphorylation [105]. eEF2 kinase (eEF2K)-mediated eEF2 phosphorylation on the 
threonine 56 (Thr56) residue inhibits its ability to interact with ribosomes, therefore 
impairing translation elongation and protein synthesis. eEF2K is a calcium/calmodulin-
dependent (CaM) α kinase. Hypoxia or prolyl hydroxylase inhibition was reported to 
activate eEF2K kinase activity, thereby contributing to increased eEF2 phosphorylation 
[106]. As a result, cells demonstrate decreased translation elongation and protein synthesis 
under hypoxia, which protects them from excessive usage of ATP. On the other hand, under 
normoxic condition, eEF2K can be hydroxylated on proline 98 residue (Pro98) that will 
disrupt its binding with calmodulin and inhibit its kinase activity (Fig. 7A). Therefore, eEF2 
cannot be efficiently phosphorylated and protein synthesis can proceed.
In summary, eEF2K serves as the protective mechanism for cells undergoing oxygen 
deprivation or ischemic condition. Consistent with this hypothesis, eEF2K knockout neurons 
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showed increased usage of ATP and greater apoptosis when exposed to hypoxic condition 
[106]. This is the first report that eEF2K hydroxylation can affect its kinase activity and also 
provides some mechanistic insight on how cells rely on eEF2K for surviving under hypoxic 
conditions. In keeping with this notion, a previous study reported that eEF2K is protective 
for hypoxic cardiac muscle cells [107]. In a cancer setting that is characterized by hypoxia, 
eEF2K may also provide a protective mechanism to allow cancer cell survival. Therefore, 
developing a specific eEF2K inhibitor may be helpful for specifically killing these hypoxic 
cancer cells. However, it remains to be determined which prolyl hydroxylase may mediate 
the eEF2K hydroxylation and whether eEF2K hydroxylation would affect its binding with 
the pVHL E3 ligase complex.
2.9 Nonmuscle actin prolyl hydroxylation
Actin is very important for eukaryotic cell movement. Actin exists in three α isoforms and 
one γ isoform that are selectively expressed in certain cell types [108]. In addition, actin 
also constists of nonmuscle β and γ isoforms that are universally expressed in most cell 
types [108]. β and γ-actin isoforms were shown to be hydroxylated by PHD3/EglN3 on 
proline 307 (Pro307) and proline 322 (Pro322) residues, which impaired actin 
polymerization [109]. As a result, depletion of PHD3/EglN3 with multiple shRNAs led to 
increased F-actin expression and cell motility in HeLa cells. In addition, this regulation was 
largely dependent on PHD3/EglN3 activity (Fig. 7B). Therefore, this work solidifies the role 
of PHD3/EglN3 as a tumor suppressor in a cancer setting by inhibiting actin polymerization 
and cell motility [109]. Consistently, PHD3/EglN3 expression was shown to be 
downregulated in multiple cancers, including colon, melanoma and breast cancers [110, 
111]. By regulating actin hydroxylation and cell motility, it is likely that PHD3/EglN3 may 
act as a tumor suppressor, inhibiting cell invasion and metastasis in these cancers. It will also 
be interesting to characterize additional PHD3/EglN3 substrates beside nonmuscle actin that 
may play an important role in cancer cell invasion and metastasis.
2.10 Thyroid hormone receptor alpha prolyl hydroxylation
By interacting with PHD2/EglN1 and PHD3/EglN3, thyroid hormone receptor α (TR-α) 
was reported to be hydroxylated at two proline residues, 160 and 162 (Pro160 and Pro162) 
[112]. Inhibition of TR-α hydroxylation (by hypoxia, for example) can increase its binding 
with the transcriptional nuclear receptor corepressor 2 (NCOR2). As a result, it leads to 
decreased transcription of phospholamban (PLN). In ischemic condition, decreased PLN in 
the heart leads to abnormal CaMKII activation, which can potentiate cardiomyocyte 
apoptosis and hypertrophy. In a physiologically relevant condition, PHD2/EglN1 and PHD3/
EglN3 knockout mice showed an elevation in PLN expression in the heart and displayed a 
cardiac hypertrophy phenotype. It still remains to be determined whether PHD2/EglN1 or 
PHD3/EglN3 can directly hydroxylate TR-α on these proline residues. In addition, TR-α 
proline hydroxylation does not change its protein level or stability. Rather, it changes the 
interaction with the nuclear receptor corepressor 2 (NCOR2) and affects PLN transcription, 
which provides a new mechanistic insight on how prolyl hydroxylation can affect a range of 
biological pathways, from canonical protein stability to protein-protein binding complexes.
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2.11 p53 prolyl hydroxylation
The tumor protein p53 gene (Tp53) is one of the most important tumor suppressors that is 
mutated in more than 50% of tumors. PHD1/EglN2 depletion was shown to sensitize colon 
cancer cells to chemotherapy drug treatment such as fluoracil (5-FU), characterized by 
enhanced apoptosis [113]. Interestingly, this enhanced response is dependent on intact p53 
and p53 phosphorylation on the serine 15 (Ser15) residue, which was normally increased by 
chemotherapy drug treatment. Upon PHD1/EglN2 depletion, p53 Ser15 phosphorylation is 
decreased following 5-FU treatment when compared to control [113]. Similar results were 
obtained when treating cells with the pan-hydroxylase inhibitor DMOG, suggesting that 
Ser15 phosphorylation was regulated by prolyl hydroxylase activity [113].
Mechanistically, Deschoemaeker et al. [113] showed that reduced p53 hydroxylation 
impaired p53 phosphorylation induced by the proline-directed Ser/Thr MAP kinase p38α. 
p53 hydroxylation is essential for p38 binding with p53 and induces p53 phosphorylation on 
Ser15. However, it remains unclear whether p53 can serve as a direct PHD1/EglN2 
substrate. In essence, this paper shows a causal link between PHD1/EglN2 silencing and 
reduced p53-mediated DNA repair following chemotherapy. Therefore, PHD1/EglN2 
inhibition can be used as a therapeutic intervention strategy in colon cancer in combination 
with chemotherapy. Together with previous report that PHD1/EglN2 regulates cyclin D1 in 
breast tumorigenesis in an enzymatic-dependent manner [33], these findings strongly 
support the development of specific PHD1/EglN2 inhibitors in cancer therapy.
2.12 CERKL prolyl hydroxylation
Ceramid kinase-like (CERKL) is an understudied protein involved in oxidative stress and 
mitochondrial signaling [114]. For example, CERKL interacts with the mitochondrial 
thioredoxin (TRX2) and activates its important functions in the mitochondria. Accordingly, 
depletion of CERKL leads to retinal degeneration due to oxidative damage in both human 
and mouse models. However, the regulation of CERKL remains largely unknown. Chen et 
al. [115] found that CERKL was ubiquitinated, which was mediated by the pVHL E3 ligase 
complex. Depletion of VHL leads to increased CERKL protein levels. In addition, some 
preliminary data suggested that PHD1/EglN2 and PHD3/EglN3 might be important for 
regulating CERKL protein stability, possibly through hydroxylation [115]. It still remains to 
be determined whether PHD1/EglN2- and PHD3/EglN3-regulated CERKL hydroxylation 
may mediate its protein stability controlled by pVHL. In addition, the physiological 
relevance of CERKL in human diseases, such as cancer, remains to be further determined.
2.13 Filamin A prolyl hydroxylation
Hypoxia was reported to induce reversible spine regression, an effort by neurons to avoid the 
energy crisis by decreasing synaptic transmission [116]. Filamin A (FLNA) is an important 
actin cross-linker. The FLNA/F-actin ratios promote orthogonal networks or parallel actin 
bundles [117]. As such, FLNA regulates many aspects of neuronal pathways, including 
dendritic morphogenesis, neuronal migration and axonal growth cone [118–120]. The role of 
FLNA in spine regression remains largely unclear.
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Segura et al. [116] showed that under normoxic conditions, PHD2/EglN1 promotes FLNA 
hydroxylation on multiple proline residues, including Pro2309, Pro2316 and possibly 
Pro2312, which will lead to FLNA binding with pVHL E3 ligase complex and degradation 
by the proteasome. Inhibition of PHD2/EglN1 activity by genetic approach (PHD2/EglN1 
loss), pharmacological approach (such as DMOG) or physiological relevant condition (such 
as hypoxia) can lead to FLNA stabilization and immature filopodium-like dendritic 
protrusion, therefore inducing spine regression and reduced synaptic density [116]. Since 
FLNA has to be precisely regulated in order to prevent neurological defects, PHD2/EglN1 -
mediated FLNA hydroxylation and its subsequent regulation by pVHL provides a molecular 
mechanism for its tight regulation in neurological context in vivo [116].
2.14 p53 lysine hydroxylation
Wang et al. [121] recently reported that the tumor suppressor protein p53 physically 
associates with the Jumonji C domain-containing protein JMJD6. As a result, JMJD6 
hydroxylates p53 on the lysine 382 (Lys382) residue, leading to inhibition of its 
transcriptional activity [121]. JMJD6 depletion induces cell apoptosis and G1-phase cell 
cycle arrest, increases the sensitivity to cell death induced by DNA damaging agents and 
inhibits p53-dependent colon cell proliferation [121].
Of note, several types of human cancers, especially colon cancer, show an upregulation of 
JMJD6 expression, and elevated JMJD6 nuclear localization positively correlates with the 
aggressiveness of colon adenocarcinomas [121]. This finding suggests that JMJD6 could be 
considered as a therapeutic target in colon cancer, but more in-depth investigations are 
warranted to pinpoint the critical role of JMJD6 in tumorigenesis.
3. Conclusion and future perspectives
Until recently, protein hydroxylation was largely considered as a relatively specialized post-
translational modification of the extracellular collagens and proteins with collagen-like 
sequences. The finding that the HIFs can be hydroxylated and, more importantly, that such 
modification strongly affects their signaling, has led to the hypothesis that post-translational 
hydroxylation may play a more prominent role than once we thought. Over the last two 
decades, the combination of in silico genomic analysis, protein association methods and 
pharmacological substrate-trapping followed by mass spectrometry analysis has allowed the 
discovery of several novel hydroxylation substrates, confirming the notion that protein 
hydroxylation extensively influences signaling pathways. In most cases, hydroxylation has 
been shown to modify protein stability, either altering the interaction with protein 
deubiquitinases (e.g. FOXO3a) or ubiquitin ligases (e.g. NDRG3, EPOR, MAPK6), or 
indirectly preserving the composition of ubiquitin ligase complexes (e.g. DYRK1A/B). 
However, hydroxylation can also affect the enzymatic activity of certain proteins, perturbing 
their interaction with direct activators (e.g. eEF2K) or influencing the occurrence of other 
post-translational modifications that in turn affect their activity (e.g. Akt, TR-α and p53). 
Moreover, protein binding pattern or homeostasis can be altered by hydroxylation, as 
evidenced by the example of OTUB1.
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In general, proline hydroxylation leads to altered protein stability (such as for HIF-αs and 
FOXO3a) and asparagine hydroxylation contributes to altered protein-protein interactions 
(such as HIF-αs and OTUB1). However, the recent reports summarized above suggest that 
proline hydroxylation can also influence protein-protein interactions and other post-
translational modifications (as illustrated by the examples of Akt, TR-α and eEF2K). These 
non-canonical functions of proline (or asparagine) hydroxylation remain to be further 
explored in future in-depth studies. The technical improvement of the last few years should 
enable a large-scale discovery of novel substrates, thus allowing a better understanding of 
how protein hydroxylation affects cell signaling and, in a larger perspective, cell 
pathophysiology.
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Highlights
Protein hydroxylation is catalyzed by 2-oxoglutarate-dependent 
dioxygenases.
A canonical example is HIFα proline hydroxylation by PHD/EglNs.
PHD/EglN inhibitors have been shown to exhibit therapeutic potential.
Protein hydroxylation can affect protein stability and protein-protein 
interaction.
Targeting protein hydroxylation could be a strategy for the treatment of 
cancers.
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Figure 1. HIF-1α regulation by hydroxylation
(A) In the presence of oxygen, HIF-1α is hydroxylated by the prolyl hydroxylases PHD/
EglN1, 2, 3 on prolines 402 and 564. This leads to HIF-1α recognition by the ubiquitin 
ligase complex composed of the von Hippel Lindau protein (cullin2) and RBX1 (RING-
box1), which promotes the polyubiquitination of HIF-1α followed by its proteasomal 
degradation. (B) The lack of oxygen prevents the hydroxylation of HIF-1α by PHD, leading 
to its stabilization. HIF-1α can then migrate to the nucleus and associate with ARNT (aryl 
hydrocarbon receptor nuclear translocator) and the cofactor p300/CBP (cyclic AMP 
response element-binding protein). The HIF-1 complex binds to and induces the 
transcription of genes containing hypoxia-responsive elements (HRE) in their promoter 
region. (C) FIH (factor inhibiting HIF) can hydroxylate HIF on the asparagine 803 (Asn803) 
residue, which affects its binding with the transcriptional co-activator p300/CBP, thereby 
inhibiting HIF transcriptional activity.
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Figure 2. FOXO3a regulation by hydroxylation
(A) The prolyl hydroxylase PHD1/EglN2 hydroxylates FOXO3a (Forkhead box-O3a) 
transcription factor on two proline residues (Pro426 and 437), thus preventing the binding 
with USP9x (ubiquitin specific peptidase 9, X-linked) deubiquitinase. This promotes 
FOXO3a ubiquitination and proteasomal degradation. (B) In the case of low activity levels 
of EglN2 (PHD1), e. g. under hypoxia, USP9x binds to FOXO3a thus preventing its 
ubiquitination and increasing its stability. FOXO3a being a transcriptional repressor for 
cyclin D1, its stabilization leads to a decreased cyclin D1 expression.
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Figure 3. DYRK1A/B regulation by hydroxylation
(A) PHD1/EglN2 triggers DYRK1A and B (dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinases 1A and B) hydroxylation, thus promoting their phosphorylation and kinase 
activity. Subsequently, ID2 (inhibitor of differentiation 2) is phosphorylated and prevented 
from interacting with pVHL ubiquitinase complex, therefore preserving pVHL-dependent 
HIF-2α ubiquitination and proteasomal degradation. (B) Under hypoxia or PHD1 depletion, 
DYRK1A and B cannot be efficiently hydroxylated or phosphorylated, thus preventing ID2 
phosphorylation on Thr27. This promotes ID2 binding with pVHL that disturbs the scaffold 
protein CUL2 interaction with pVHL E3 ligase complex. As a consequence, pVHL cannot 
efficiently ubiquitinate HIF-2α. HIF-2α accumulation is then followed by transcriptional 
regulation of its downstream target gene expression.
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Figure 4. NDRG3 regulation by hydroxylation
(A) NDRG3 (N-Myc downstream-regulated gene) can be hydroxylated on proline 294, 
potentially by PHD2/EglN1. The hydroxylated NDRG3 binds to pVHL, which promotes 
NDRG3 ubiquitination and degradation. (B) Hypoxia can lead to the accumulation of lactate 
that directly binds NDRG3, thus preventing its interaction with the pVHL complex. 
Therefore, NDRG3 is stabilized and may contribute to downstream RAF-ERK1/2 kinase 
signaling.
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Figure 5. Akt regulation by hydroxylation
(A) Akt can be hydroxylated on Pro125 and Pro313 residues by PHD2/EglN1. pVHL and 
the phosphatase PP2A interact with hydroxylated Akt and inhibit Akt activity, as 
demonstrated by the decrease of Akt phosphorylation on threonine 308 (Thr308). (B) The 
lack of oxygen or functional pVHL prevents Akt hydroxylation and binding with pVHL and 
PP2A, therefore leading to the increase of Akt Thr308 phosphorylation and activity and 
contributing to increased cell proliferation and tumorigenesis.
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Figure 6. EPOR, MAPK6 and RIPK4 regulation by hydroxylation
(A) PHD3/EglN3 -mediated prolyl hydroxylation on EPOR (erythropoietin receptor) Pro419 
and Pro426 residues facilitates EPOR binding with pVHL complex, hereby causing its 
proteasomal degradation. PHD3/EglN3 depletion stabilizes EPOR and, therefore, stimulates 
JAK/STAT signaling pathway-driven erythropoiesis. (B) MAPK6 (Mitogen-activated protein 
kinase 6) can be hydroxylated by PHD3/EglN3 on proline 25 (Pro25), which potentially 
leads to its dissociation from HUWE1 (HECT, UBA and WWE domain containing 1) E3 
ubiquitin protein ligase, thus protecting it from proteasomal degradation. (C) RIPK4 
hydroxylation by FIH affects RIPK4 activity, therefore contributing to Wnt signaling 
pathway activity modulation.
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Figure 7. eEF2K, β and γ-actin regulation by hydroxylation
(A) Under normoxic condition, eEF2K (eukaryotic elongation factor 2 kinase) can be 
hydroxylated on proline 98 (Pro98), which disrupts its binding with calmodulin and inhibits 
its kinase activity. Therefore, eEF2 cannot be efficiently phosphorylated and protein 
synthesis proceeds. Hypoxic condition prevents eEF2K hydroxylation, allowing eEF2K 
interaction with calmodulin. Activated eEF2K phosphorylates eEF2 on threonine 56 (Thr56) 
therefore inhibiting its translation elongation activity. (B) β and γ-actin isoforms are 
hydroxylated by PHD3/EglN3 on Pro307 and Pro322 residues, which reduces actin 
polymerization. PHD3/EglN3 depletion leads to increased F-actin expression and cell 
motility in HeLa cells.
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Table 1
Mouse Models of Key Proline or Asparagine Hydroxylases
Genotype Type of knockout Phenotype Reference
PHD1/EglN2−/− • Global constitutive • Viable, 
apparently 
normal
• Normal 
erythropoiesis
• Hypoxia 
tolerance due to 
glucose 
metabolic twitch 
From ojddarWe 
towards 
anaerobic ATP 
production, 
allowing 
reduced 
generation of 
oxidative stress
• Takeda et al., 
2006 [19]
• Talteda et al., 
2007 [54]
• Aragonés et 
al., 2008 [55]
PHD2/EglN1−/− • Global constitutive
• Broad-spectrum 
conditional
• Epidermal or dermal tissue-
specific
• Myeloid-specific
• Embryonic 
lethal, severe 
heart and 
placenta defects
• Increased 
vascular density 
and lumen sizes
• Severe 
erythrocytosis 
due to renal 
EPO pathway 
activation
• Wound healing 
improvement 
and ischemic 
injury resistance 
via HIF-1α-
mediated 
transcription of 
angiogenic 
factors
• HIF-1α-
mediated pro-
atherogenic 
phenotype 
characterized by 
increased 
expression of 
adhesion 
molecules on 
granulocytes 
and monocytes
• Takeda et al., 
2006 [19]
• Takeda et al., 
2007 [54]
• Takeda et al., 
2008 [56]
• Zimmermann 
et al., 2014 
[58], 
Kalucka et 
al., 2013 [57]
• Pflueke et 
al., 2013 [60]
PHD3/EglN3−/− • Global constitutive • Viable, 
apparently 
normal
• Normal 
erythropoiesis
• Takeda et al., 
2006 [19]
• Takeda et al., 
2007 [54]
PHD1/EglN2−/−
PHD3/EglN3−/−
• Global constitutive • Moderate 
erythrocytes is d 
ue to the 
activation of the 
• Talteda et al., 
2008 [56]
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Genotype Type of knockout Phenotype Reference
hepatic 
HIF-2α/EPO 
pathway
FIH−/− • Global constitutive
• Neuron-specific conditional
• Reduced body 
weight, elevated 
metabolic rate, 
hyperventilation, 
improved 
glucose and 
lipid 
homeostasis, 
resistant to high-
fat-diet-induced 
weight gain and 
hepatic steatosis
• Reduced body 
weight, elevated 
metabolic rate, 
improved 
glucose 
homeostasis, 
resistant to high-
fat-diet-induced 
weight gain
• Zhang et al., 
2010 [61]
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Table 2
List of Recently Identified Hydroxylation Targets
Protein Potential hydroxylase Hydroxylated residues Effects of hydroxylation Reference
FOXO3a PHD1/EglN2 Pro426, Pro437 Dissociation from USP9x 
deubiquitinase, FOXO3a 
proteasomal degradation and 
subsequent cyclinD1 stabilization
Zheng et al. [87]
DYRK1A, DYRK1B PHD1/EglN2 Unknown Increase of DYRK1A/B 
phosphorylation and kinase activity, 
disruption of phosphorylated ID2 
interaction with pVHL. HIF2a 
ubiquitination and degradation
Lee et al. [90]
NDRG3 PHD2/EglN1 Pro294 Increased association with pVHL, 
subsequent NDRG3 ubiquitination 
and degradation, decrease of 
NDRG3-regulated RAF-ERK1/2 
kinase signaling
Lee et al. [94]
Akt PHD2/EglN1 Pro125, Pro313 Increased interaction with pVHL 
and PP2a phosphatase, decrease Akt 
phosphorylation on Thr308 and 
Ser473 residues and therefore 
impaired Akt activity, subsequent 
decrease of Akt-mediated cell 
proliferation and tumorigenesis
Guo et al. [98]
EPOR PHD3/EglN3 Pro419, Pro426 Increased binding with pVHL, 
EPOR proteasomal degradation, 
subsequent decrease of EPO-
induced JAK-STAT signaling 
pathway and erythropoiesis
Heir et al. [103]
OTUB1 FIH Asn22 Alteration of OTUB1 interaction 
with proteins important in cellular 
metabolism
Scholz et al. [104]
MAPK6 PHD3/EglN3 Pro25 Dissociation from E3 ligase 
HUWE1 and subsequent MAPK6 
protein stabilization
Rodriguez et al. 
[80]
RIPK4 FIH Asn Modification of RIPK4 kinase 
activity, increased Wnt signaling 
pathway activity
Rodriguez et al. 
[80]
eEF2K Unknown Pro93 Disruption of eEF2K-calmodulin 
complex, subsequent inhibition of 
eEF2K kinase activity and 
preservation of eEF2-dependent 
translation elongation and protein 
synthesis
Moore et al. [106]
β and γ actin PHD3/EglN3 Pro307, Pro322 Impairment of actin polymerization Luo et al. [109]
TR-α PHD2/EglN1, PHD3/EglN3 Pro160, Pro162 Increased TR-α interaction with 
transcriptional co-repressor 
NCOR2, increased transcription of 
PLN
Xie et al. [112]
p53 PHD1/EglN2 Unknown Binding with p33, phosphorylation 
on p53 Ser15
Deschoemaeker et 
al. [113]
CERKL PHD1/EglN2, PHD3/EglN3 Unknown Regulation of CERKL protein 
stability
Chen et al. [115]
FLNA PHD2/EglN1 Multiple Pro residues Increased binding with pVHL E3 
ligase and FLNA proteasomal 
degradation.
Segura et al. [116]
p53 JMJD6 Lys382 Inhibition of p53 transcriptional 
activity
Wang et al. [121]
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